Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth citrate + carbomer is a pharmaceutical complex used primarily in rectal formulations for the treatment of inflammatory bowel conditions. It combines bismuth citrate, which possesses antimicrobial and cytoprotective properties, with carbomer (a polyacrylate polymer) that serves as a mucoadhesive agent to enhance local delivery and retention in the distal gastrointestinal tract. Bismuth compounds exert therapeutic effects through multiple mechanisms, including the disruption of bacterial cell walls, inhibition of enzymes such as urease, and the provision of a protective coating on the inflamed mucosa. This combination has been clinically evaluated for distal ulcerative colitis and chronic pouchitis, where it aims to reduce mucosal inflammation and bacterial load. In clinical trials, it has demonstrated efficacy comparable to standard treatments like 5-aminosalicylic acid (5-ASA) without evidence of systemic bismuth accumulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth citrate + carbomer.